Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2008

View Archived Issues

Genz-29155 and sirolimus combination synergistic in renal transplant model

Studies reveal neurological effects of berberine

Effects of LY-450139 on Abeta studied with novel labeling agent 13C6-leucine

Durable safety and efficacy seen with belatacept in phase II study

Studies report efficacy of alternative regimens of enteric-coated mycophenolate in transplantation

Superior characteristics of P2Y12 inhibitor PRT-060128 detailed

Novel therapeutic agents for neurological disorders divulged in recent patents

GlaxoSmithKline reports on efforts to identify GlyT-1 inhibitors for schizophrenia

Baxter enters U.S. licensing agreement for Innocoll's gentamicin surgical implant for SSIs

FDA reports two new cases of PML in patients receiving Tysabri as monotherapy for MS

Novavax presents favorable results from phase I/IIa pandemic influenza vaccine trial

New treatment options for cancer reported in recent patent literature

CE mark for Cypher Select Plus in acute myocardial infarction

Phase IIa study of CK-1827452 successfully completes interim safety analysis

Recent Novartis patent describes new agents for respiratory disorders

Cell Genesys terminates VITAL-2 GVAX trial in advanced prostate cancer

Genmab to initiate four ofatumumab studies

M2e universal influenza vaccine candidate shows safety and immunogenicity

NexMed decides not to submit NDA for NM-100060

Pain Therapeutics and King Pharmaceuticals develop a new abuse-resistant pain medication

Photocure presents positive phase II results with Visonac for acne

Protherics commences phase IIa Prolarix study in liver cancer

Algeta presents phase II data on pain palliation with alpharadin

Arana completes enrollment in phase II ART-621 trial in psoriasis

Merck and Intercell commence phase II clinical trial of V-710 in S. aureus infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...